Sam Brusco, Associate Editor11.07.23
Johnson & Johnson MedTech revealed plans to submit its Ottava robotic surgical system for an investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) in the back half of 2024 to begin clinical trials.
The Ottava robot, according to J&J, was engineered to save operating room (OR) space and create simple, flexible workflows while using J&J MedTech company Ethicon’s instrumentation. The company cited Ethicon’s decades of innovation and strong market presence for minimally invasive surgery, as well as its expertise in device-to-tissue and user-to-device interactions.
Ottava’s four robotic arms are integrated into a standard-size surgical table. The robotic arms can be either left up when needed, or stowed under the surgical table when not.
A “twin motion” feature—unified movement of the surgical table and robotic arms—can help to reposition a patient without delaying the procedure, according to J&J. The company also said it will provide its global team of specialists in surgical education and clinical training to help surgeons learn to operate Ottava.
“We believe the future of surgery is personal,” J&J MedTech’s company group chairman of Robotics & Digital Hani Abouhalka told the press. “Starting with the human impact—the connection between the patient, surgeon, and OR staff— we are unlocking what science and technology can do to improve the surgical experience and health outcomes for everyone involved. OTTAVA is designed to consistently deliver this experience in any OR globally.”
When launched, Ottava will join J&J MedTech’s Monarch platform and Velys robotic-assisted solution in its portfolio of robotic surgical products.
The Ottava robot, according to J&J, was engineered to save operating room (OR) space and create simple, flexible workflows while using J&J MedTech company Ethicon’s instrumentation. The company cited Ethicon’s decades of innovation and strong market presence for minimally invasive surgery, as well as its expertise in device-to-tissue and user-to-device interactions.
Ottava’s four robotic arms are integrated into a standard-size surgical table. The robotic arms can be either left up when needed, or stowed under the surgical table when not.
A “twin motion” feature—unified movement of the surgical table and robotic arms—can help to reposition a patient without delaying the procedure, according to J&J. The company also said it will provide its global team of specialists in surgical education and clinical training to help surgeons learn to operate Ottava.
“We believe the future of surgery is personal,” J&J MedTech’s company group chairman of Robotics & Digital Hani Abouhalka told the press. “Starting with the human impact—the connection between the patient, surgeon, and OR staff— we are unlocking what science and technology can do to improve the surgical experience and health outcomes for everyone involved. OTTAVA is designed to consistently deliver this experience in any OR globally.”
When launched, Ottava will join J&J MedTech’s Monarch platform and Velys robotic-assisted solution in its portfolio of robotic surgical products.